PROM1 and non-small cell lung carcinoma: The recent finding has shown that MSC-based delivery of TRAIL can target and eliminate CD133+ non-small-cell lung carcinoma (NSCLC)-derived cancer stem cells (CSCs) by modifying mitochondria membrane potential, and subsequently triggering intrinsic apoptosis in CSCs (116).